An Open-Label, Dose-Escalation, Phase 1/2 Study of the Oral Form of Ixazomib (MLN9708), a Second-Generation Proteasome Inhibitor, Administered in Combination With Lenalidomide and Low-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Requiring Systemic Treatment

Trial Profile

An Open-Label, Dose-Escalation, Phase 1/2 Study of the Oral Form of Ixazomib (MLN9708), a Second-Generation Proteasome Inhibitor, Administered in Combination With Lenalidomide and Low-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Requiring Systemic Treatment

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 31 Aug 2017

At a glance

  • Drugs Ixazomib (Primary) ; Dexamethasone; Lenalidomide
  • Indications Multiple myeloma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Takeda Oncology
  • Most Recent Events

    • 28 Aug 2017 Planned End Date changed from 1 Jun 2017 to 19 Oct 2017.
    • 12 Aug 2017 Data from this and other trials (NCT00932698, NCT00963820, NCT01564537) was used to quantitatively characterize the benefit-risk profile of ixazomib in relapsed/refractory MM, results published in the Targeted Oncology
    • 25 Jun 2017 Updated efficacy and long-term safety results for patients who did not withdraw from the study in order to receive stem cell transplantation, presented at the 22nd Congress of the European Haematology Association.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top